a_frontpage Copy
The treatment
AVLX-144
Clinical trials progressing
We are a biotechnology company developing innovative treatments for acute conditions such as acute ischemic stroke (AIS) and subarachnoid haemorrhage (SAH). In October 2020 we administered a first dose of our lead compound AVLX-144 to a human volunteer in a Phase 1 clinical study.
Acute ischemic stroke is a leading cause of death and disability worldwide with few treatment options available, while subarachnoid haemorrhage is a particular form of stroke and an orphan indication. Based on positive results from our extensive preclinical characterization of AVLX-144 and our first clinical trials results we are convinced that we have a unique opportunity to make a transformative difference for patients,
Current Status
AVLX-144
18
Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)
18k
Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)
124m
Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)
18k
Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)
Get in touch
Frontpage
Developing best in class neuroprotectants
Avilex Pharma are developing best in class neuroprotectants, exploring an exciting and promising drug target in the brain.
Successfully completes phase 1 clinical trial
Avilex Pharma successfully completes its phase 1 clinical trial of AVLX-144 - a potentially game-changing treatment for acute neurological…
